Suppr超能文献

患者对中重度特应性皮炎治疗的偏好。

Patient Preferences in the Treatment of Moderate-to-severe Atopic Dermatitis.

机构信息

Royal free London NHS Foundation Trust, London, United Kingdom.

Sunnybrook Health Sciences Centre, Division of Dermatology, Toronto, Canada.

出版信息

Acta Derm Venereol. 2024 Feb 21;104:adv24339. doi: 10.2340/actadv.v104.24339.

Abstract

Atopic dermatitis is a chronic, inflammatory skin disease. A variety of systemic treatments are available for patients with moderate-to-severe atopic dermatitis. The efficacy, safety and administration profile of these treatments vary, and determining the optimal treatment strategy may require weighing the benefits and drawbacks of therapies with diverse characteristics. This study used an online discrete choice experiment survey to investigate treatment preferences among adults with atopic dermatitis from Denmark, France, the UK, or Canada. Participants were identified through existing online panels. The survey included questions regarding different treatment attributes, defined based on currently approved treatments for moderate to severe atopic dermatitis. Treatment preferences were measured as the relative importance of different treatment attributes. A total of 713 respondents met the inclusion criteria and completed the survey. The discrete choice experiment identified a significant preference for avoiding the risk of severe adverse events, and for oral pill every day compared with biweekly injections. The time to full effect was not rated as being important. These findings suggest that patients with moderate-to-severe atopic dermatitis prioritize safety as most important, followed by ease of administration in their treatment preferences, while time to full effect and monitoring requirements were the least important attributes.

摘要

特应性皮炎是一种慢性炎症性皮肤病。对于中重度特应性皮炎患者,有多种全身治疗方法可供选择。这些治疗方法的疗效、安全性和管理概况各不相同,确定最佳治疗策略可能需要权衡具有不同特征的疗法的利弊。本研究使用在线离散选择实验调查,调查了来自丹麦、法国、英国或加拿大的特应性皮炎成人患者的治疗偏好。参与者通过现有的在线小组确定。该调查包括有关不同治疗属性的问题,这些属性是基于目前批准的中重度特应性皮炎治疗方法定义的。治疗偏好被衡量为不同治疗属性的相对重要性。共有 713 名符合纳入标准的受访者完成了调查。离散选择实验确定了对避免严重不良事件风险以及与每两周一次注射相比每天口服药丸的显著偏好。完全起效的时间并不被认为是重要的。这些发现表明,中重度特应性皮炎患者在治疗偏好中最看重安全性,其次是管理的便利性,而完全起效的时间和监测要求则是最不重要的属性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c4d/10910525/373d547e3f92/ActaDV-104-24339-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验